TY - JOUR
T1 - Targeting the MDM2-p53 protein-protein interaction with prenylchalcones
T2 - Synthesis of a small library and evaluation of potential antitumor activity
AU - Brandão, Pedro
AU - Loureiro, Joana B.
AU - Carvalho, Sylvie
AU - Hamadou, Meriem Hadjer
AU - Cravo, Sara
AU - Moreira, Joana
AU - Pereira, Daniela
AU - Palmeira, Andreia
AU - Pinto, Madalena
AU - Saraiva, Lucília
AU - Cidade, Honorina
N1 - Publisher Copyright:
© 2018 Elsevier Masson SAS
PY - 2018/8/5
Y1 - 2018/8/5
N2 - Prenylation of several bioactive scaffolds is a very interesting strategy used in Medicinal Chemistry in order to improve biological/pharmacological effects. A small library of prenylchalcones was synthesized and evaluated for the ability to inhibit the MDM2-p53 interaction using a yeast-based assay. The capacity of all synthesized prenylchalcones and their non-prenylated precursors to inhibit the growth of human colon tumor HCT116 cells was also evaluated. The obtained results led to the identification of a hit compound, prenylchalcone 2e, which behaved as potential inhibitor of the MDM2-p53 interaction in yeast, and showed improved cytotoxicity against human tumor cells expressing wild-type p53, including liver hepatocellular carcinoma HepG2, breast adenocarcinoma MCF-7, and malignant melanoma A375 cells. In colon cancer cells, it was also shown that the growth inhibitory effect of prenylchalcone 2e was associated with the induction of cell cycle arrest, apoptosis, and increased protein expression levels of p53 transcriptional targets. Moreover, computational docking studies were performed in order to predict docking poses and residues involved in the MDM2-p53 potential interaction.
AB - Prenylation of several bioactive scaffolds is a very interesting strategy used in Medicinal Chemistry in order to improve biological/pharmacological effects. A small library of prenylchalcones was synthesized and evaluated for the ability to inhibit the MDM2-p53 interaction using a yeast-based assay. The capacity of all synthesized prenylchalcones and their non-prenylated precursors to inhibit the growth of human colon tumor HCT116 cells was also evaluated. The obtained results led to the identification of a hit compound, prenylchalcone 2e, which behaved as potential inhibitor of the MDM2-p53 interaction in yeast, and showed improved cytotoxicity against human tumor cells expressing wild-type p53, including liver hepatocellular carcinoma HepG2, breast adenocarcinoma MCF-7, and malignant melanoma A375 cells. In colon cancer cells, it was also shown that the growth inhibitory effect of prenylchalcone 2e was associated with the induction of cell cycle arrest, apoptosis, and increased protein expression levels of p53 transcriptional targets. Moreover, computational docking studies were performed in order to predict docking poses and residues involved in the MDM2-p53 potential interaction.
KW - Antitumor activity
KW - MDM2-p53 inhibitors
KW - Prenylated chalcones
UR - http://www.scopus.com/inward/record.url?scp=85050109867&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2018.07.037
DO - 10.1016/j.ejmech.2018.07.037
M3 - Article
C2 - 30041135
AN - SCOPUS:85050109867
SN - 0223-5234
VL - 156
SP - 711
EP - 721
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
ER -